P
eroxisome proliferator activated receptors (PPAR) are members of the nuclear receptor superfamily and at least three subtypes have been identified (PPARα, PPARδ, and PPARγ). 1 PPARγ is expressed at a high level in adipocytes and has been shown to be an important regulator of adipocyte differentiation and fatty acid metabolism. 2 PPARγ forms a heterodimer with retinoid X receptor (RXR) and regulates expression of target genes by binding to the PPAR responsive element. 3 It has been demonstrated that 15-deoxy-∆ 12,14 -prostaglandin J 2 (15d-PGJ 2 ), a metabolite of prostaglandin D 2 , is a potential endogenous ligand for PPARγ, and that thiazolidinediones (synthetic antidiabetic agents) such as troglitazone (TGZ) and pioglitazone are specific exogenous ligands for PPARγ. 3 4 PPARγ is also expressed at high levels in colonic epithelial cells and colon cancer cells. 5 6 Sarraf and colleagues 7 showed that activators of PPARγ suppress the growth response of colon cancer cells. Brockman and colleagues 8 reported that activation of PPARγ leads to inhibition of anchorage independent growth of colon cancer cells. Kitamura and colleagues 9 also showed in HT-29 colon cancer cells that activation of PPARγ results in upregulation of differentiation marker genes such as villin and intestinal alkaline phosphatase. On the other hand, Saez and colleagues 10 and Lefebvre and colleagues 11 showed in APC MIN mice, an animal model of familial polyposis, that treatment with PPARγ ligands increases the frequency and size of colon polyps. Although the results of these in vitro and in vivo studies are contradictory, it is very likely that the PPARγ pathway can modulate the growth response of colon epithelial cells and colon cancer cells. As a better understanding of PPARγ signalling in colon cancer cells will benefit the development of new strategies for colon cancer prevention and treatment, we investigated the characteristics of PPARγ ligand induced growth suppression and apoptosis in colon cancer cells.
MATERIALS AND METHODS

Reagents
Wy-14643, carbaprostacyclin (cPGI), and 15d-PGJ 2 were obtained from Cayman Chemical (Ann Arbor, Michigan, USA). TGZ was provided by Sankyo Pharmaceuticals (Tokyo, Japan). The caspase inhibitor (apopain inhibitor II), Z-Asp(OMe)-Glu(OMe)-Val-DL-Asp(OMe)-fmk, was obtained from Takara (Shiga, Japan). Cycloheximide (CHX), all-trans retinoic acid (AT-RA), 9-cis-retinoic acid (9c-RA), and wortmannin were purchased from Wako Pure Chemical (Osaka, Japan). NS-398 was provided by Taisho Pharmaceuticals (Tokyo, Japan). Cell culture HT-29 cells were obtained from Dainippon Pharmaceuticals (Tokyo, Japan). Cells were grown in Ham's F-12 culture medium (Gibco BRL, Rockville, Maryland, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco BRL). When experiments were performed in the absence of FBS, FBS was eliminated 24 hours before initiating the experiments.
Western blot analysis HT-29 cell monolayers were washed twice with phosphate buffered saline (PBS) and scraped in a modified radioimmunoprecipitation buffer containing 50 mM Tris HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA, 1 mM phenylmethylsulphonyl fluoride, 1 µg/ml aprotinin, 1 mM Na 3 VO 4 , and 1 mM NaF. Supernatants of the cell lysates (50 µg protein/lane) were separated by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis. After proteins were transferred to a polyvinylidene difluoride membrane (Clear blot membrane-P; Atto, Tokyo, Japan), the membrane was blocked with TTBS (10 mM Tris HCl (pH 7.6), 150 mM NaCl, and 0.1% Tween 20) containing 5% non-fat dry milk for one hour at room temperature. The membrane was then incubated with goat polyclonal anti-PPARα, anti-PPARδ, or anti-PPARγ antibody (Santa Cruz Biotechnology, California, USA) in TTBS containing 5% non-fat dry milk overnight at 4°C. After being washed with TTBS, the membrane was incubated with horseradish peroxidase conjugated antigoat IgG antibody (Santa Cruz Biotechnology) in TTBS containing 5% non-fat dry milk for one hour at room temperature. The membrane was washed again and the specific band was visualised with LumiGLO chemiluminescent reagent (New England BioLabs, Beverly, Massachusetts, USA).
Assay for cell growth response and cell viability
The effects of the PPAR ligands on DNA synthesis of cells were assessed using the cell proliferation ELISA kit (Roche Diagnostics, Tokyo, Japan). This assay is a colorimetric immunoassay for quantification of cell proliferation based on measurement of bromodeoxyuridine (BrdU) incorporation during DNA synthesis, and is a non-radioactive alternative to the [ 3 H] thymidine incorporation assay. Cells were grown in 96 well culture dishes (10 4 cells/well), incubated with the PPAR ligands for 24 hours, and then labelled with BrdU for a further six hours. Incorporated BrdU was measured colorimetrically.
Cell viability was assessed with WST-1 reagent (Wako Pure Chemical). This assay is based on cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenase of viable cells to a formazan dye. Cells grown in 96 well culture plates (10 4 cells/ well) were incubated with test agents for 24 hours and WST-1 reagent was then added to each well. Culture plates were further incubated for two hours and cell viability was assessed colorimetrically.
Quantitative determination of fragmented DNA in cytoplasm was performed with the cell death ELISA kit (Roche Diagnostics). This ELISA detects the amount of cytoplasmic histone associated DNA fragments. Cells grown in 96 well culture plates (2×10 4 cells/well) were incubated with test agents for 18 hours, supernatant culture medium was then removed, and lysis buffer was added to each well. The assay was performed according to the manufacturer's manual, and the amount of fragmented DNA was measured colorimetrically.
cDNA array experiments Changes in HT-29 cell gene expression associated with PPARγ induced apoptosis were screened with cDNA array membranes (ATLAS Human Apoptosis Array; Clontech, Palo Alto, California, USA). Cells were treated with TGZ (30 µM) or 15d-PGJ 2 (10 µM) for eight hours and total RNA was extracted with Trizol reagent (Gibco BRL). Poly(A) + RNA was further isolated with Micro-Oligo(dT) Cellulose Spin Columns (5 Prime-3 Prime, Boulder, Colorado, USA). Poly(A) + RNA isolated from each sample (1 µg) was converted to 32 P labelled first strand cDNA using [α-32 P]dATP (∼110 Tbq/mmol) (Amersham-Pharmacia Biotech, Uppsala, Sweden). cDNA probes were hybridised to the ATLAS array membranes according to the manufacturer's instruction. Autoradiography and densitometric analysis were performed using a BAS2000 Bioimaging System (Fujix, Tokyo, Japan).
Real time quantitative reverse transcription-polymerase chain reaction (RT-PCR)
Real time quantitative RT-PCR analysis was performed to confirm the results of cDNA array experiments. Total RNA was isolated from cells with Trizol reagent (Gibco BRL) and first strand cDNA was made with You-Prime First Strand Beads (Amersham-Pharmacia Biotech) using oligo(dT) primers (Gibco BRL). PCR primers were designed according to the reported sequences and are summarised in table 1.
Real time quantitative RT-PCR analysis was performed in an ABI PRISM 7700 Sequence Detection System (PE Biosystems, Tokyo, Japan) using SYBR Green PCR reagents (PE Biosystems). In this assay, the fluorescence intensity of SYBR Green dye, which corresponds to the amount of PCR products, is monitored. After an initial 10 minutes at 95°C, the reaction was run for 40 PCR cycles of 15 seconds at 95°C and one minute at 56°C (two step PCR). β-actin mRNA quantification was also performed for standardisation. To prepare standard samples for quantitative RT-PCR, conventional RT-PCR was performed and PCR products were purified with Quiaquick PCR Purification Kits (Quiagen, Hilden, Germany). Purified PCR products were diluted and used as standard samples (6×10 2 to 6×10 7 copies) for generating a standard curve for each quantitative PCR experiment.
Statistics
Data are expressed as mean (SD). Analysis of variance (ANOVA) was performed when more than two groups were compared, and when significant (p<0.05), Scheffés multiple comparison test was applied to test for differences between individual groups. A p value <0.05 was considered to be significant.
RESULTS
Expression of PPAR subtypes in HT-29 cells
To confirm expression of PPAR subtypes (PPARα, PPARδ, and PPARγ), western blot analysis was performed using HT- suggesting that PPARα and PPARδ are not critically involved in the growth response of HT-29 cells. In contrast, PPARγ ligands 15d-PGJ 2 (1-100 µM) and TGZ (1-100 µM) suppressed BrdU incorporation significantly in a dose dependent manner.
Effects of PPARγ ligands on HT-29 cell viability
We then examined whether 15d-PGJ 2 We also examined the effect of cycloheximide (CHX). Cells were preincubated with CHX (25 µM) for two hours, and further incubated with TGZ (20 µM) in the continued presence of CHX. As shown in fig 4C, TGZ induced cell death was partially prevented by CHX. As CHX is an inhibitor of protein synthesis, this result suggests that the action of TGZ is mediated, at least in part, by de novo protein synthesis.
Effects of 9c-RA and AT-RA As PPARγ forms a heterodimer with RXR and regulates expression of target genes by binding to the PPAR responsive element, we tested the effects of 9c-RA, a specific ligand for RXR, on the viability of HT-29 cells. We also tested the effects of AT-RA, a ligand for the retinoid A receptor (RAR), for comparison. Cells were incubated with 9c-RA (10 µM) or AT-RA (10 µM) in combination with 15d-PGJ 2 (10 µM) or TGZ (20 µM) for 24 hours. As shown in fig 5, 9c -RA alone or AT-RA alone did not cause a significant decrease in cell viability, and HT-29 cell death induced by 15d-PGJ 2 (10 µM) or TGZ (20 µM) was not affected by coincubation with 9c-RA (10 µM) or AT-RA (10 µM).
cDNA array experiments
To examine the effects of the PPARγ ligands on expression of apoptosis related genes in HT-29 cells, we screened gene expression profiles before and after eight hours of treatment with 15d-PGJ 2 (10 µM) or TGZ (30 µM) using cDNA arrays (ATLAS Human Apoptosis Arrays; Clontech). Using this screening method, we identified several genes whose expression appeared to be modulated by TGZ or 15d-PGJ 2 . Because quantitative assessment is difficult in cDNA array experiments, we performed real time quantitative RT-PCR analysis using an ABI PRISM 7700 sequence detection system to confirm the results of the cDNA array experiments. Data on expression of c-myc, c-jun, and gadd153 are given below.
Real time quantitative RT-PCR analysis
The real time quantitative RT-PCR system employed is based on measurement of fluorescence signal and fig 6 shows representative standard curves plotting the log starting target copy number of c-myc, c-jun, gadd153, and β-actin mRNA and threshold cycles (Ct, PCR cycle number at which the fluorescence signal reached above baseline). β-actin mRNA measurement was performed in all samples for standardisation of the data. Interaction between cell survival signalling and PPARγ signalling As already shown in fig 3, 15d-PGJ 2 and TGZ induced HT-29 cell death was partially antagonised in the presence of FBS. This may be due to the presence of cell protective substances contained in FBS, such as peptide growth factors. Growth factor linked cell survival signalling has been reported to be mediated by the phosphatidylinositol 3-kinase (PI3-kinase)/Akt pathway. 12 Cyclooxygenase 2 (COX-2) is also assumed to be important in antiapoptotic signalling in colon cancer cells. 13 Thus we examined the effects of inhibitors of PI3-kinase (wortmannin) and COX-2 (NS-398) on TGZ induced HT-29 cell death in the presence of 10% FBS. We also tested the effect of a mitogen activated protein (MAP) kinase inhibitor (PD98059) because interaction between the MAP kinase pathway and PPARγ has been suggested. 14 Figure 8A shows the effects of wortmannin (10 µM). Although wortmannin alone did not affect HT-29 cell viability, TGZ at 100 µM caused significant cell death in the presence of wortmannin compared with that in the absence of wortmannin. Figure 8B Induction of apoptosis by PPARγ ligands has been reported in several cell types, including macrophages, 15 endothelial cells, 16 breast cancer cells, 17 and choriocarcinoma cells. 18 In the present study, we showed that PPARγ ligands induced apoptosis in HT-29 cells and that cell death induced by PPARγ ligands was antagonised when serum was present in the culture medium. Bishop-Bailey 16 observed the protective effects of serum against PPARγ ligand induced apoptosis in endothelial cells. This may be explained by the presence of polypeptide growth factors and other cell protective substances contained in serum. Consistent with this, we found that wortmannin, an inhibitor of PI3-kinase, antagonised the protective effect of serum, suggesting a possible interaction between PPARγ signalling and PI3-kinase mediated cell survival signalling. 12 Further studies are required to confirm this finding. Although the molecular mechanisms of PPARγ induced apoptosis are not clear, Chinetti and colleagues 15 showed that, in macrophages, PPARγ inhibits the transcriptional activity of the nuclear factor κB p65/RelA subunit, and speculated that PPARγ activators induce macrophage apoptosis by negatively interfering with the antiapoptotic nuclear factor κB signalling pathway. Elstner and colleagues 17 showed that apoptosis induced by the combination of TGZ and AT-RA was associated with downregulation of bcl-2 in MCF-7 breast cancer cells. We screened for the effects of the PPARγ ligands on expression of apoptosis related genes using cDNA arrays. We did not find visible changes in mRNA levels of bcl family genes after incubation with 15d-PGJ 2 or TGZ (data not shown). We selected several genes whose expression appeared to be modulated by PPARγ ligands prior to induction of apoptosis, and confirmed A series of genetic alterations are associated with the development of colon cancers. 19 Most colorectal tumours are initiated by inactivating mutations in the adenomatous polyposis coli (APC) tumour suppressor gene, which is located on 5q21. 19 APC is a cytoplasmic protein and the tumour suppressive effect of APC is believed to be mediated by its ability to bind to β-catenin. 20 Mutations of β-catenin have also been identified in colon cancer cells which lack APC mutations. β-catenin binds to the T cell factor/lymphoid enhancer factor (Tcf/Lef) transcription factors and activates expression of genes containing Tcf/Lef binding sites in their regulatory regions. 22 23 Wild-type APC binds to β-catenin and promotes the degradation of β-catenin which results in inhibition of β-catenin-Tcf/Lef regulated gene transcription. 24 As mutated APC (or mutated β-catenin) is deficient in this ability, increased β-catenin-Tcf/Lef mediated transcription is closely associated with colonic tumorigenesis. Since Kolligs and colleagues 25 recently showed that γ-catenin is also regulated by APC and that γ-catenin activates the transcription of Tcf/Lef target genes, γ-catenin may also play an important role in colonic tumorigenesis.
Although the target genes of β-catenin-Tcf/Lef are not fully understood, He and colleagues 26 identified the c-myc gene as a target of this signalling. It is also reported that c-myc expression is greatly enhanced by γ-catenin-Tcf/Lef.
25 c-Myc protein is an oncogenic transcription factor and expression of c-myc mRNA and c-Myc protein are frequently altered in various cancers. 27 Although c-myc is reported to be overexpressed in most colon cancers, 28 rearrangement and amplification of this gene are rare in colon cancers. 29 Thus deregulation of the APC/β-catenin pathway may be responsible for overexpression of c-myc in colon cancers. Consistent with this, He and colleagues 26 showed that introduction of wild-type APC to HT-29 cells results in downregulation of c-myc expression. The present study demonstrated that PPARγ ligands, 15d-PGJ 2 and TGZ, both significantly downregulated expression of c-myc prior to induction of apoptosis in HT-29 cells. Thus it is very likely that in colon cancer cells, activation of PPARγ signalling can compensate for deregulation of c-myc expression induced by altered APC/β-catenin and/or APC/γ-catenin signalling.
Mann and colleagues 30 have reported that c-jun and fra-1 are also targets of β-catenin-Tcf/Lef. c-jun and fra-1 proto oncogenes are components of AP-1 transcription factor and regulate expression of many genes. As the present results showed that PPARγ ligands upregulate expression of c-jun, PPARγ signalling does not appear to counteract the altered APC/β-catenin signalling in the case of c-jun expression. However, in certain cell types, 31 32 c-jun has also been reported to be associated with cell cycle arrest and apoptosis. Further studies may be required to evaluate the significance of c-jun in the growth regulation of colon cancer cells. We also identified in the present study that PPARγ ligands upregulate expression of gadd153 prior to induction of apoptosis. Expression of gadd153 is induced by a variety of DNA damaging and growth arrest inducing agents and is also associated with apoptosis in various cell types. 33 34 He and colleagues 35 recently showed that PPARδ is a target of APC/β-catenin signalling, suggesting the involvement of PPARδ in colonic tumorigenesis. However, in the present study, cPGI, a ligand for PPARδ, did not affect the growth response of HT-29 cells. Thus further studies are required to understand the significance of PPARδ signalling and its interaction with PAPRγ signalling.
In conclusion, the present results, together with reports by other investigators, 7-9 suggest a potential usefulness of PPARγ ligands for chemoprevention and treatment of colon cancers. Further basic as well as clinical studies are required to develop new strategies to fight colon cancers using PPARγ ligands.
